Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
The Lancet. Gastroenterology & Hepatology|August 19, 2024
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trialKlara Dorman, Stefan Boeck, Karel Caca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized TrialHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2009
A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumorsGeorge D Demetri, Paolo G Casali, Jean-Yves Blay, et al.
European Journal of Cancer Care|August 3, 2021
Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa)Martin Eichler, Daniel Pink, Franka Menge, et al.
Cancer|April 17, 2014
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinibHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
International Journal of Cancer|April 28, 2020
Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)Sylvie Lorenzen, Jorge Riera Knorrenschild, Claudia Pauligk, et al.
British Journal of Cancer|January 21, 2022
The association of Health-Related Quality of Life and 1-year-survival in sarcoma patients-results of a Nationwide Observational Study (PROSa)Martin Eichler, Susanne Singer, Leopold Hentschel, et al.
JAMA|March 29, 2012
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trialHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
International Journal of Cancer|March 8, 2023
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIMThorsten O Goetze, Ralf-Dieter Hofheinz, Timo Gaiser, et al.
Frontiers in Endocrinology|September 15, 2023
Health related Quality of Life over time in German sarcoma patients. An analysis of associated factors - results of the PROSa studyMartin Eichler, Leopold Hentschel, Susanne Singer, et al.
Pageof 7